NCT00910728View on ClinicalTrials.gov

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

August 31, 2014

Conditions
Primary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis
Interventions
DRUG

AZD1480

Oral capsule 2.5 mg, 10 mg and 40 mg

Trial Locations (3)

Unknown

Research Site, New York

Research Site, Houston

Research Site, Villejuif

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

University of Texas

OTHER

collaborator

New York City Hoffman Center

UNKNOWN

collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

lead

AstraZeneca

INDUSTRY